The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
First US surgeries performed in October
LONDON, Nov. 2, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of its LEGION CONCELOC Cementless Total Knee System (TKS) and first completed surgical procedures.
CONCELOC Advanced Porous Titanium is a patented, proprietary, 3D printed porous structure technology first used in Smith+Nephew's leading REDAPT™ Revision Hip System, launched in 2016. CONCELOC is created in a virtual environment and manufactured through 3D printing additive manufacturing to optimize its porous structure to promote bony ingrowth.1-4 https://www.prnewswire.co.uk/news-releases/smith-nephew-introduces-the-legion-tm-conceloc-tm-cementless-total-knee-system-with-proprietary-3d-printed-advanced-porous-titanium-technology-874931212.html
Motley fool recommendation today
Smith & Nephew’s (LSE: SN) another FTSE 100 stock I believe provides brilliant value today. In fact, I’d buy it before the healthcare giant releases third-quarter financials on November 4. I think another share-price-boosting update could be coming down the pipe.
Smith & Nephew — which is primarily known for manufacturing artificial limbs and joints — has traded strongly since Covid-19 eased in many regions and elective surgery procedures picked up again. Most recent financials showed revenues rocketed 48.2% in the second quarter, up from 11.5% in quarter one.
City analysts think Smith & Nephew’s earnings will also leap 21% in 2022. This leaves it trading on a forward PEG ratio of just 0.8. This represents excellent value, given that global healthcare spending is poised to rise strongly in the years ahead.
I also think the company’s role in developing surgical robotic technology will pay off handsomely. I’d buy Smith & Nephew despite the threat posed to elective surgery rates by the ongoing pandemic.
Christmas has come early. It’s allowed me to load up with some more of these nuggets at bargain prices!
So the fall on no news is now the rise on no news. Fun and games.
Stryker is up 110% off the covid low,S&N is up 19%.
There is no doubt that Covid has impacted growth, the Question is,is it temporary ?
My bet is it is,there is a growing market for S&N products,The market is the market,I am a buyer.
Anywhere between £10 -£13 are good entry points and should be rewarded over the next 12-18 mths IMHO.
I am not a blind bull here,there are always risks,but a bull I am.
Best of luck folks.
Apologies it was in response to the previous post: Been watching this stock for a while and trying to figure out what a good entry point is. Today's drop (so far) should be related to Stryker results
I am a little concerned by this drop, insider knowledge that the trading update isn’t as good as expected? Must be a large sell that will show up later?
Any major advance can only proceed with as few Pis on board as possible,its just the way things are and how markets work.
Stop us out,make us fearful etc etc.this is a decent company and if next week is poorly received I will add when the dust settles.
Its business is a growth business and any set back should be seen as temporary and an opportunity to build a position always in the context of not being overexposed by taking on too big a size.
Best of luck
Perhaps nervousness ahead of results, more narrative about delays and hope for 2022 in the trading report with jam tomorrow.
Many others view this as temporary and will treat weakness as an opportunity to add as a LT core investment.
Who know who will win the day, but with the daily moves here, taking a position is the position to take :)
Big drop takes out the t10 and t20 traders who were speculating before Nov 4th t/u. Should bounce quickly.
Rude not to have a little top up @ 1248.75 !
Any explanation for a 3% drop?
No news, no big sells, doesn't make a lot of sense.
Hoping that was a market shake ahead of results picking up the weak stop losses. GLA.
Leapfrog - frog look like it missed the lily pad ahead of results.
Topping up though as this is my pension.
No need as it's a foregone that it will leapfrog forward imo before 3rd quarter results/update next Thursday......will comment again when my next marker falls at £14 (probably early in November). Kind regards...
Adastra, will you re-post your previous BB comment when the company "smashes" through the 1300 barrier again?
Yeah there are a few people here with a very bullish outlook.
Seems we've all been loading up at the silly low prices.
It's still a great entry price, and I will continue adding each month at anything sub £16.
Well done guys!
Good to see the turn for sure and dividends picked up.
At these levels this will be on the New Year tips list for sure.
GLA
As I said in my post 3165 on 11th Oct, having loaded up and exhaustedly highlighted this share at £12.49......I'd be back as it smashed through £13, here I am. Only three weeks later that marker has fallen. I expect £14 to follow quickly and then £15 and £16. Do the research and get on board, loads of upside beckons as should be confirmed in the t/u due on 4th Nov. Happy days.....back at £14.